BioSpace News Archive

Global WholeHealth Partners Corp. (OTC PINK: GWHP) announced today that it is authorized to sell FDA EUA Authorized SARS-COV-2 IgG/IgM Antibody Whole Blood, Serum and Plasma Rapid Test.

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced that it has received approval from Health Canada for the sale of BAUSCH + LOMB ULTRA® ONE DAY daily disposable silicone hydrogel contact lenses.

Mr. Carlos Lugo promoted to Vice President of Quality and CMC Regulatory Operations Mr. Devendra Luhar promoted to Vice President of Manufacturing & Plant Operations

-Former Director of the Office of New Drugs at the FDA’s Center for Drug Evaluation and Research, brings extensive regulatory expertise and experience to Provention-

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced the appointment of Dominic Smethurst, MA, MBChB, MRCP, MFPM as Chief Medical Officer. Dr. Smethurst brings to Bicycle extensive expertise in developing bispecific immuno-oncology agents, as well as

Obesity in expectant mothers may hinder the development of the babies’ brains as early as the second trimester, a new study finds.

Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP; OTCQB:ASPCF) today reported its financial results for the three and six-month period ended June 30, 2020. Unless otherwise noted, all amounts are in US dollars and are prepared in accordance with International Financial Reporting Standards (“IFRS”). Second Quarter Highlig

Opdivo is the first and only PD-1 inhibitor to demonstrate superior overall survival and progression-free survival in combination with chemotherapy when compared to chemotherapy alone in patients with gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma

All evenamide pre-clinical studies requested by FDA completed and first clinical safety study initiated; on track to initiate evenamide Phase III program in 2021 In advanced evaluation of opportunities to broaden pipeline of treatments for central and peripheral nervous system diseases International conference call for investors and analysts today at 3:00 PM CET/ 9:00 AM ET MILAN & MORRISTOWN, N.J.--( BUSINESS WIRE )-- Ne

Accurate identification of antibiotic resistance markers based on the ARESdb QIAGEN CLC Module leveraging Ares Genetics’ proprietary antibiotic resistance database Pathogens correctly identified with 100% sensitivity and specificity, antibiotic resistance markers with >95% sensitivity and >99% specificity, respectively Study paves the way for routine clinical diagnostic application of next-generation sequencing (NGS) in timely as well as accurate infectious disease testing and drug